Utama › Kanser Pankreas › Massachusetts
Kajian klinikal Kanser Pankreas di Massachusetts
47 kajian untuk Kanser Pankreas sedang mencari peserta di lokasi di Massachusetts.
Bandar di Massachusetts
Teks kajian rasmi (Bahasa Inggeris)
Distance-Based Exercise to Preserve Function and Prevent Disability
- Dana-Farber Cancer Institute, Boston
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07059884A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Massachusetts General Hospital, Boston
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06465069Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
- Dana-Farber Cancer Institute, Boston
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05372614A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Dana-Farber Cancer Institute - Oncology Department, Boston
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06760819A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute - Chestnut Hill, Newton
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT07090499A Study of PHN-012 in Patients With Advanced Solid Tumors
- PHN-012-001 Site, Boston
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT07127874Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
- Dana Farber Cancer Institute, Boston
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07621718Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute (DFCI), Boston
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07252232Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Dana Farber Cancer Institute, Boston
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06128551Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06445062A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
- Investigative Site US022, Boston
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07522073Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
- Dana-Farber Cancer Institute, Boston
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Sep 2026 · NCT06271291A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- Massachusetts General Hospital - Main Campus, Boston
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Sep 2026 · NCT07629960Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- Dana-Farber Cancer Institute, Boston
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT07349537A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Local Institution - 0124, Boston
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT07492680Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
- Boston Children's Hospital, Boston
Mengambil pesertaKajian pemerhatian
Sehingga umur 17 · Semua jantina · Dikemas kini 11 Sep 2026 · NCT06651580Resilience and Equity in Aging, Cancer, and Health (REACH)
- Dana-Farber Cancer Institute, Boston
Mengambil peserta
Umur 65 ke atas · Semua jantina · Dikemas kini 10 Sep 2026 · NCT04674267A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT07644559Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
- Dana-Farber Cancer Institute, Brookline
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT05245500Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, Boston
Mengambil pesertaFasa 1/2
Umur 18 hingga 130 · Semua jantina · Dikemas kini 12 Ogo 2026 · NCT05417594Pancreatic Cancer Early Detection Consortium
- Massachusetts General Hospital, Boston
- Umass Memorial Medical Center, Worcester
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 18 hingga 90 · Semua jantina · Dikemas kini 22 Jul 2026 · NCT04970056A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
- Dana-Farber/Massachusetts General Hospital, Inc, Boston
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Jul 2026 · NCT07300150A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Jun 2026 · NCT07458347Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 19 hingga 110 · Semua jantina · Dikemas kini 29 Jun 2026 · NCT02012699A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
- Research Site, Boston
- Research Site, Boston
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Jun 2026 · NCT06835569Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
- Dana Farber Cancer Institute, Boston
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Jun 2026 · NCT04890613Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Jun 2026 · NCT06040541Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Mengambil pesertaFasa awal 1Sukarelawan sihat dialu-alukan
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Mei 2026 · NCT06122896Video Education With Result Dependent dIsclosure
- Dana Farber Cancer Institute, Boston
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Mei 2026 · NCT05225428Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Dana Farber Cancer Institute, Boston
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Mei 2026 · NCT05379985Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Mei 2026 · NCT06239194A Study of MGC028 in Participants With Advanced Solid Tumors
- Mass General Brigham, Boston
- Dana Farber/Harvard Cancer Center, Boston
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Apr 2026 · NCT06723236A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Massachusetts General Hospital, Boston
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Apr 2026 · NCT07020221Prehab for Pancreatic Cancer Surgery
- UMass Memorial Medical Center, Worester
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Apr 2026 · NCT07478185Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
- Beth Israel Deaconess Medical Center - Division of Hematology/Oncology, Boston
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Apr 2026 · NCT06850623A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- Dana-Farber Cancer Institute, Boston
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Mac 2026 · NCT06244771Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
- Massachusetts General Hospital, Boston
Mengambil pesertaFasa 2
Umur 18 hingga 80 · Semua jantina · Dikemas kini 27 Feb 2026 · NCT04485286Resistance Exercise Combined With Protein Supplementation in People With Pancreatic Cancer: The RE-BUILD Trial
- Dana Farber Cancer Institute, Boston
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Feb 2026 · NCT05356117A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
- Ohio State University-Telemedicine, Boston
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Feb 2026 · NCT06906562The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
- Beth Israel Deaconess Medical Center, Boston
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Feb 2026 · NCT06861088Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.